Seattle Genetics (SGEN) Tops Q3 EPS by 8c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BofA/Merrill Lynch Upgrades Seattle Genetics (SGEN) to Neutral
October 27, 2017 6:15 AM EDTBofA/Merrill Lynch upgraded Seattle Genetics (NASDAQ: SGEN) from Underperform to Neutral with a price target of $70.00 (from $55.00).
Analyst Tazeen Ahmad believes the Adcetris product will be more positive in the LT and remains constructive on uptake.
For an analyst ratings... More
